Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics is a small clinical-stage biotech house building antivirals and metabolic drugs, early on in proving efficacy but assembled around real unmet medical needs in liver disease and viral infection.

The company crystallized around two founding insights: first, that legacy hepatitis B therapies work but don’t cure the disease, leaving patients on treatment for life; second, that metabolic liver dysfunction—now reclassified as MASH (metabolic dysfunction-associated steatohepatitis)—is a massive global problem with few approved drugs. Aligos’ science team came together to address both, plus pandemic lessons about preparedness for coronaviruses. The play is small-cap clinical biotech: no approved products, revenue-less, betting on three to five programs hitting clinical milestones over the next few years.

Pipeline and stage

Pevifoscorvir sodium, a capsid assembly modulator, is the lead candidate in Phase 2b trials for chronic HBV—the most advanced program. ALG-055009, a THR-ß agonist, is in Phase 2a for MASH and obesity signals. ALG-097558, a ritonavir-free pan-coronavirus protease inhibitor, completed Phase 1 for pandemic preparedness. Earlier programs in the lab address fibrosis and other liver comorbidities. Each milestone—enrollment completion, efficacy signals, safety data—moves the needle on valuation; a clinical setback can crater it.

Capital structure and burn

Like nearly all development-stage biotech firms, Aligos burns cash monthly on R&D, clinical operations, and regulatory affairs. The company has raised capital through public markets (IPO in 2020) and private placements to fund operations. Equity investors are funding the R&D lab until—and only if—a product shows enough efficacy to justify commercialization and then eventual profitability. The company has no near-term revenue, so traditional metrics like P/E or dividend yield are meaningless; the story is all probability-weighted phase transitions and cash runway.

At a glance

• Clinical-stage biotech, not approved drugs yet
• Lead program (pevifoscorvir) in Phase 2b for HBV
• MASH/obesity program (ALG-055009) in Phase 2a
• Pan-coronavirus protease inhibitor completed Phase 1
• Heavily dependent on clinical trial success and capital markets for funding
• Founded 2018, IPO 2020, headquartered South San Francisco